Cargando…
Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia
Children with multiple relapsed or refractory leukemia have dismal survival. Research has identified engagement of immune checkpoint receptors (e.g., PD-1, PD-L1 and CTLA-4) as a mechanism for treatment resistance. For adult cancer, inhibitors of PD-1 (nivolumab) and CTLA-4 (ipilimumab) have shown p...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410023/ https://www.ncbi.nlm.nih.gov/pubmed/30863527 http://dx.doi.org/10.2217/ijh-2018-0009 |
_version_ | 1783402134444703744 |
---|---|
author | Broglie, Larisa Gershan, Jill Burke, Michael J |
author_facet | Broglie, Larisa Gershan, Jill Burke, Michael J |
author_sort | Broglie, Larisa |
collection | PubMed |
description | Children with multiple relapsed or refractory leukemia have dismal survival. Research has identified engagement of immune checkpoint receptors (e.g., PD-1, PD-L1 and CTLA-4) as a mechanism for treatment resistance. For adult cancer, inhibitors of PD-1 (nivolumab) and CTLA-4 (ipilimumab) have shown promise with response rates ranging from 7 to 40%. In vitro studies using acute myeloid leukemia cell lines have shown that acute myeloid leukemia blasts may similarly utilize the PD-1/PD-L1 axis to evade an anticancer immune response. We report the first case of a pediatric patient with multiple relapsed/refractory leukemia treated with nivolumab, ipilimumab and 5-azacytidine who tolerated therapy with brief improvement of symptoms. |
format | Online Article Text |
id | pubmed-6410023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Future Medicine Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-64100232019-03-12 Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia Broglie, Larisa Gershan, Jill Burke, Michael J Int J Hematol Oncol Case Report Children with multiple relapsed or refractory leukemia have dismal survival. Research has identified engagement of immune checkpoint receptors (e.g., PD-1, PD-L1 and CTLA-4) as a mechanism for treatment resistance. For adult cancer, inhibitors of PD-1 (nivolumab) and CTLA-4 (ipilimumab) have shown promise with response rates ranging from 7 to 40%. In vitro studies using acute myeloid leukemia cell lines have shown that acute myeloid leukemia blasts may similarly utilize the PD-1/PD-L1 axis to evade an anticancer immune response. We report the first case of a pediatric patient with multiple relapsed/refractory leukemia treated with nivolumab, ipilimumab and 5-azacytidine who tolerated therapy with brief improvement of symptoms. Future Medicine Ltd 2019-01-16 /pmc/articles/PMC6410023/ /pubmed/30863527 http://dx.doi.org/10.2217/ijh-2018-0009 Text en © 2019 Michael J. Burke This work is licensed under a Creative Commons Attribution-NonCommercial NonDerivative 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Case Report Broglie, Larisa Gershan, Jill Burke, Michael J Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia |
title | Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia |
title_full | Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia |
title_fullStr | Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia |
title_full_unstemmed | Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia |
title_short | Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia |
title_sort | checkpoint inhibition of pd-l1 and ctla-4 in a child with refractory acute leukemia |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410023/ https://www.ncbi.nlm.nih.gov/pubmed/30863527 http://dx.doi.org/10.2217/ijh-2018-0009 |
work_keys_str_mv | AT broglielarisa checkpointinhibitionofpdl1andctla4inachildwithrefractoryacuteleukemia AT gershanjill checkpointinhibitionofpdl1andctla4inachildwithrefractoryacuteleukemia AT burkemichaelj checkpointinhibitionofpdl1andctla4inachildwithrefractoryacuteleukemia |